



THE CHAIM SHEBA MEDICAL CENTER  
AT TEL HASHOMER

*The Hospital of Israel*



*The 4<sup>th</sup> Friends of Israel*  
**UROLOGICAL SYMPOSIUM**  
Tel Aviv, Israel • July 3-5, 2018

# LiST for ED Updatde

**Noam D. Kitrey, MD, FECSM**

Dept. of urology, Sheba medical center, ISRAEL

Chairman of the EAU UroTrauma guidelines panel

# Main points

Data from the last 3-4 years

- How does it work?
- Does it work?
- For whom?
- Who's the enemy?
- What's next?

Basic science

Clinical evidence

Target population

Misconceptions

Future research

**How does it work?**

# Low-intensity shockwaves mechanism of action

## THE HYPOTHESIS




Occlusion  
of arterioles  
in the corpora  
cavernosa



Low-intensity  
shockwaves  
initiate the process  
of angiogenesis




New arterioles lead  
to improved arterial  
inflow and better  
erections



doi:10.1038/nrurol.2017.119  
 Published online 25 Jul 2017

# Low-intensity Shockwaves Therapy (LiST) for Erectile Dysfunction 6 putative mechanisms of action\*



\*summary on the hypotheses reported on published basic research articles

# Animal models for LiST

- Diabetic rats were treated with SW / sildenafil / both
- Acute sildenafil and Li-ST significantly improved erectile responses
- Measured by ICP and AUC/MAP
- Surprisingly, this effect **is not mediated by a NO/cGMP - dependent mechanism**
- The **combination of LiST with sildenafil significantly potentiated the effect** of LiST alone

**Does it work?**

**Clinical evidence**



# Pilot - proof of the concept study

58/2 August 2010 issue of European Urology

available at [www.sciencedirect.com](http://www.sciencedirect.com)  
journal homepage: [www.europeanurology.com](http://www.europeanurology.com)



## Sexual Medicine

### **Can Low-Intensity Extracorporeal Shockwave Therapy Improve Erectile Function? A 6-Month Follow-up Pilot Study in Patients with Organic Erectile Dysfunction**

*Yoram Vardi<sup>\*</sup>, Boaz Appel, Giris Jacob, Omar Massarwi, Ilan Gruenwald*

*Neuro-Urology Unit, Rambam Healthcare Campus and the Technion, Haifa, Israel*

2012

# LiST: first sham-controlled study

of THE JOURNAL  
UROLOGY®



Official Journal of the  
American  
Urological  
Association

Sexual Function/Infertility

## **Does Low Intensity Extracorporeal Shock Wave Therapy Have a Physiological Effect on Erectile Function? Short-Term Results of a Randomized, Double-Blind, Sham Controlled Study**

Yoram Vardi,<sup>\*</sup>† Boaz Appel, Amichai Kilchevsky and Ilan Gruenwald

*From the Neuro-Urology Unit, Rambam Healthcare Campus, and the Rappaport Faculty of Medicine, Technion – IIT, Haifa, Israel (YV, BA, AK, IG), and the Department of Urology, Yale-New Haven Hospital, New Haven, Connecticut (AK)*

# LiST is effective in PDE5i non-responders

of THE JOURNAL  
UROLOGY®



Official Journal of the  
American  
Urological  
Association

## Penile Low Intensity Shock Wave Treatment is Able to Shift PDE5i Nonresponders to Responders: A Double-Blind, Sham Controlled Study



Noam D. Kitrey,<sup>\*,†</sup> Ilan Gruenwald,<sup>\*</sup> Boaz Appel,<sup>‡</sup> Arik Shechter,<sup>\*</sup> Omar Massarwa<sup>\*</sup> and Yoram Vardi<sup>‡</sup>

- 54% of the LIST group achieved erection hard enough for vaginal penetration [EHS = 3]
- No patient in the sham group had EHS = 3 ( $p < 0.0001$ ).
- LIST was effective in 40.5% of men treated according to IIEF-EF MCID (Minimal Clinically Important Difference) vs. none in the sham group ( $p < 0.001$ ).

# LiST changes penile hemodynamics

Low-Intensity Shockwave Therapy Improves Hemodynamic Parameters in Patients With Vasculogenic Erectile Dysfunction: A Triplex Ultrasonography-Based Sham-Controlled Trial

Dimitrios Kalyvianakis, MD, FECSM, and Dimitrios Hatzichristou, MD, PhD, FECSM



# For how long?

## Low Intensity Shock Wave Treatment for Erectile Dysfunction—How Long Does the Effect Last?


of THE JOURNAL  
UROLOGY®



Official Journal of the  
American  
Urological  
Association

Noam D. Kitrey,\* Yoram Vardi, Boaz Appel,† Arik Shechter, Omar Massarwi, Yasmin Abu-Ghanem and Ilan Gruenwald

**Fig 2: Maintenance of success over time according to ED severity**



# For how long?

## Low Intensity Shock Wave Treatment for Erectile Dysfunction—How Long Does the Effect Last?

of THE JOURNAL  
UROLOGY®



Official Journal of the  
American  
Urological  
Association

Noam D. Kitrey,\* Yoram Vardi, Boaz Appel,† Arik Shechter, Omar Massarwi, Yasmin Abu-Ghanem and Ilan Gruenwald

- a gradual decrease in efficacy was observed
- Only 53.5% maintained the beneficial effect after two years
- 76% of patients with mild and moderate ED, without diabetes, will preserve the beneficial effect of LIST after two years

# Randomized control trials (n=652 /211 placebo)

	Name	Date	No. of patients	Type of machine	Target population	% success	Journal
1	Vardi	2012	60	ED1000 (Medispec)	responders	58 3m	J Urol
2	Yee	2014	58	ED1000 (Medispec)	mixed	Significant <b>only in sever</b> 1 m	Int J Urol
3	Olsen	2014	105	Duolit (Storz)	responders	57 1 m	Scan J Urol
4	Sirini	2015	77	ED1000 (Medispec)	responders	78 12 m	Can J Urol <b>sponsored</b>
5	Kitrey	2016	55	ED1000 (Medispec)	Non-responders	54 at 3 m	J Urol
6	Motil	2016	125	Pyezowave (wolf)		77 1 m	Adv Sex Med <b>sponsored</b>
7	Kalyvianakis	2017	46	ED1000 (Medispec)	responders	56 6 m	J Sex Med
8	Fojecki	2017	126	Pyezowave (wolf)	mixed	<b>No effect</b> 1 m	J Sex Med

1. VardiY: J Urol. Vol. 187, 1769-1775, 2012
2. Yee CH: IntJUrol21, 1041-1045, 2014
3. Olsen AB: ScandJ Urol, 49(4): 329-333 2014
4. SiriniVS: Can j Urol, 22(1); 2016

5. KitreyND: j Urol:195(5),155015552016
6. Motill: Advanced sexual Medon line j 2016
7. kalyvianakisD: J Sex Med,14(7):891-897 2017
8. GrzegorzL:J Sex Med ,14:106-112 2017

# Published Open labeled studies

	Name	Device	Energy	Sessions	Target population	No. of patients	Success rate
1	Vardi	ED 1000 Medispec	Electrohydraulic	12	Responders	20	65%
2	Reisman	Direx Renova	Electromagnetic	4	Mixed	58	71%
3	Pelayo-Nieto	Direx Renova	Electromagnetic	4	Mixed	15	70%
4	Gruenwald	ED 1000 Medispec	Electrohydraulic	12	Non responder	33	62%
5	Chung -	Storz Duolith	Electromagnetic	12	Non-responders	30	68%
6	Frey - Fode	Storz Duolith	Electromagnetic	6	Post - prostatectomy	16	59%
7	Ruffo	Direx Renova	Electromagnetic	4	Non-responders	31	66%
8	Bechara	Direx Renova	Electromagnetic	4	Non-Responders	50	48% at 1 year
9	Tsai	Storz Duolith	Electromagnetic	12	Non-responders	52	54% 3 m
10	Kalyvianakis	Dornier Aries	Electromagnetic	6-12-18	Responders	42	62% (6 sessions) 74% (12 sessions) 83% (18 sessions)

1. Vardi Y et al (2010) EurUrol  
 2. Reisman Y et al (2014) IntJ ImpotRes  
 3. Pelayo-Nieto M et al (2015) ActasUrolEsp  
 4. Gruenwald I et al (2015) J sex Med  
 5. Chung E and Cartmill R (2015). BJU Int  
 6. Frey et al (2016) ScandJ Urology  
 7. Ruffo A et al (2015) IntBrasilJ Urol  
 8. Bachara et al (2016) J Sex Med  
 9. Tsai et al (2017) Am J Men Health  
 10. Kalyvianakis et al (2018) J Sex Med



# The Market

- **ED 1000** electrohydraulic (Medispec)




- **Urogold 100** electrohydraulic (MTS)



- **Duolith® SD1** electromagnetic (Storz)



- **Renova** linear SW electromagnetic (Direx)



- **Aries®** electromagnetic (Dornier)



- **PiezoWave2** piezoelectric (Richard Wolf)



	Karl Storz	Dornier	MTS	Medispec	Direx	Richard Wolf
Machine	Duolith SD1	Aries	Urogold100	ED1000	Renova	PiezoWave2
Technology	Electro-magnetic	Electro-magnetic	Electro-hydraulic	Electro-hydraulic	Electro-magnetic	Piezoelectric
Focal zone	Narrow focus	Wide focus	Wide focus (OP155)	Wide focus	Wide focus	Linear focus 46 x 20 x 4mm
Energy penetration depth	0 – 125 mm	0 – 70 mm	0 – 80 mm	0 – 140 mm	0 – 40 mm	0 – 172 mm
Maximum energy flux density	1.25 mJ/mm <sup>2</sup>	0.31 mJ/mm <sup>2</sup>	0.19 mJ/mm <sup>2</sup> (OP155)	0.09 mJ/mm <sup>2</sup>	0.09 mJ/mm <sup>2</sup>	0.82 mJ/mm <sup>2</sup>
Frequency	1 – 8 Hz	0.5 – 20 Hz	0.5 – 8 Hz	2-2.6 Hz	5 Hz	1-8 Hz
Applicator lifespan	Warranty: 1 M	Warranty: 2 M	100 - 200 K (estimated)	Stops at 180 K	1M (estimated)	Warranty: 5 M
Adjustable buttons on applicator	Yes	Yes	No	Yes (operating & reload)	No	Yes
Applicator weight	770g	500g	850g	1 kg	N.A. (on holder)	0.55 – 1.58

# Open questions?

- What is the best protocol, energy parameters, and energy source?
- How to cover better all corporal tissue?
- Who are the suitable patients?
- What are the real outcomes?

**Misconceptions driven by the media and industry!**

# Which treatment parameters?

- No data regarding the most effective **energy source**, type of **probe**, and no. of sessions
- Most manufacturers reduce the **no. of sessions** due to patients compliance disregarding efficacy (Between 4 to 12 sessions)
- **Energy flux density (EFD)** 0.09 - 0.25 mJ/mm<sup>2</sup>
- **Number of shockwave pulses** 1,500 - 6,000
- Is the **break** beneficial?

# How to cover better the corpora?

- This is probably the most important issue regarding success
- Every probe and type of energy have a different focus and depth
- The crura are the most tricky part




Abb.1: Primäre fokussierte oder defokussierte Behandlung



Abb. 4




Abb.2: Linienförmig fokussierte Stoßwellentherapie



Abb. 5



Linear Shockwave Tissue Coverage LSTC – Gewebendeckung durch linienförmig fokussierte Stoßwellen







Abb. 6



ature Reviews | Urology



# For whom? Who will not benefit?

- Patients without any **natural erectile response** (lack of tumescence anytime)
- **No response** to PDE5i and injections
- **Post Radical Prostatectomy?**
- **Pure neurogenic ED?**

# Can we cure ED by LiST?



## Probably not

We can **improve** erectile function  
in selected patients

With more clinical and basic research the  
effectiveness of this novel therapy will  
certainly improve



# Shifting the paradigm of ED management

- Symptom relief
- Mechanical assistance

- Disease modification
- Prevention

Traditional

Contemporary

Future



American  
Urological  
Association

## Erectile Dysfunction: AUA Guideline (2018)

*Published 2018*

### Guideline Statement 24

24. For men with ED, intracavernosal stem cell therapy should be considered investigational. (Conditional Recommendation; Evidence Level: Grade C)

# Take Home Messages

- The first non-invasive method that improves erectile mechanism (with moderate results)
- Able to replace oral treatment in patients who previously responded to PDE5i
- Able to shift PDE5i non-responders to responders
- More **BASIC SCIENCE** and **RCTs** are needed
- improved & patient friendly protocol is needed